Lymphatica Medtech develops medical devices for lymphatic disease treatment. The first product, LymphoDRAIN, is the worldwide first active lymphatic bypass for the treatment of chronic lymphedema, a disabling disease affecting millions of people worldwide.
Lymphatica developed its implantable drainage technology as a results of years of research at the Lausanne Federal Institute of Technology (EPFL) and of the Lausanne University Hospital (CHUV).

Press releases

Triacca Valentina
16. November 2022

What have you learnt? Episode 3 with Lymphaticas Valentina Triacca

What have you learnt? This is a question we’re putting to company founders from our portfolio. Because if you found a start-up, run a company, make investments or work in management, you are learning something new every single day. You also have to deal with new situations. And continue to develop new skills. To cover the latter aspect, we expanded the HTGF Academy this year to offer a comprehensive programme for company founders. And because we firmly believe in the power of peer-to-p
3. December 2020

Lymphatica Medtech raises seven-digit Series A round

LYMPHATICA Medtech, a vascular medical device development start-up, closes a seven-digit financing round to advance clinical validation aiming at revolutionizing the treatment of chronic lymphoedema. The investment round, led by High-Tech Gründerfonds, was joined by business angels, the EIT health (European Institute of Innovation and Technology) and existing investors, including LIVEventures. The Company also announces the appointment of Laurent Duhoux (ex VP New Technology at Edwards L

Info & Contact


EPFL Innovation Park – Building E
1015 Lausanne (Switzerland)

In portfolio

09. Nov 2020

HTGF Manager

Dr. Anke Caßing, Principal / Authorized Signatory